ArticlePoultry science2026
PCYT2 inhibits lipid accumulation via the notch signaling pathway in chicken primary hepatocytes.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphatidylethanolamine cytidylytransferase 2 (PCYT2) is a key enzyme for phosphatidylethanolamine synthesis and plays a critical role in lipid metabolism. Our prior study revealed that PCYT2 exhibited differential expression in chicken liver between embryonic day 14 and post-hatch day 1 . However, its function and regulatory mechanism in chicken lipid metabolism remains unclear. In this study, overexpression and knockdown assays were performed to explore the role of PCYT2 in lipid metabolism using chicken primary hepatocytes, and the regulatory mechanism was further analyzed by transcriptome sequencing. The results showed that overexpression of PCYT2 significantly reduced lipid droplet content, triglyceride and total cholesterol levels in chicken primary hepatocytes. These reductions were associated with the downregulation of lipogenic-related genes and proteins (ACC and FASN) and the upregulation of fatty acid oxidation-related genes and proteins (CPT1, ACOX1, and ACSL1). Conversely, knockdown of PCYT2 produced opposite regulatory effects. Subsequently, transcriptome sequencing results demonstrated that overexpression of PCYT2 markedly suppressed the activity of the Notch signaling pathway. Activation of the Notch signaling pathway using Jagged-1 significantly attenuated the regulatory effects of PCYT2 overexpression on lipid metabolism in chicken primary hepatocytes. Specifically, Notch activation increased lipid content, upregulated the expression level of ACC and FASN, and downregulated the expression level of CPT1, ACOX1, and ACSL1 in PCYT2-overexpressing hepatocytes. In summary, these results demonstrated that PCYT2 negatively regulates lipid accumulation in chicken primary hepatocytes by enhancing fatty acid oxidation and inhibiting lipogenesis, and the Notch signaling pathway is a critical mediator of this process. This findings provide a novel molecular target to improve hepatic lipid homeostasis and reduce fat deposition in chickens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.